Literature DB >> 31980953

Risk factors associated with progression and persistence of small- and medium-sized coronary artery aneurysms in Kawasaki disease: a prospective cohort study.

Lei Liu1,2, Chunyan Luo3, Yimin Hua1,4,5,6, Mei Wu1,2, Shuran Shao1,2, Xiaoliang Liu1,5,6, Kaiyu Zhou7,8,9,10, Chuan Wang11,12,13,14,15.   

Abstract

To identify the risk factors of progression and persistence of small- and medium-sized coronary artery aneurysm (CAA) in a contemporary cohort of patients with Kawasaki disease (KD) and to determine the relationship between CAA progression and persistence. A total of 89 KD patients with small- and medium-sized CAA were prospectively enrolled. All patients were followed up at least for 2 years by serial echocardiography. Multivariate logistic regression analysis was conducted to evaluate independent risk factors for CAA progression and persistence. A total of 46 (51.7%) and 73 (82.0%) patients showed echocardiographic CAA regression by 1 month and 24 months of follow-up, respectively. CAA progression was documented in 12 (13.5%) patients during follow-up. The initial aneurysm size according to CAA classification (OR 0.089, 95% CI 0.013-0.634, P = 0.016) and CAA progression (OR 42.618, 95% CI 3.740-485.6, P = 0.003) were independently associated with CAA persistence. The number of involved coronary arteries (OR 0.223, 95% CI 0.065-0.767, P = 0.015) and lymphocyte proportion (OR 1.327, 95% CI 1.019-1.727, P = 0.040) were independently associated with CAA progression.
Conclusion: Patients with KD and greater initial aneurysm size, CAA progression, more involved coronary arteries, and lower lymphocyte proportion may require intensive cardiac monitoring and adjuvant therapies.What is Known:• Long-term outcomes of patients with KD and CAA are primarily driven by the consequences of CAA regression and progression.• Regression and progression occurs more frequently in patients with small- and medium-sized CAAs, and less frequently for giant CAAs.What is New:• The CAA size at diagnosis, NCAI, and the proportion of lymphocytes are presumably associated with the small- and medium-sized CAA persistence or CAA progression.• The CAA progression was associated with CAA persistence.

Entities:  

Keywords:  Coronary artery aneurysm; Kawasaki disease; Progression; Prospective study; Regression; Risk factors

Mesh:

Year:  2020        PMID: 31980953     DOI: 10.1007/s00431-019-03492-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  5 in total

1.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

2.  Left ventricular assist device implantation following multisystem inflammatory syndrome in children due to SARS-CoV-2.

Authors:  Oguz Konukoglu; Ali Dogan; Kenan Sever; Arzu Akcay; Mehmet Balkanay; Denyan Mansuroglu
Journal:  J Card Surg       Date:  2022-08-03       Impact factor: 1.778

Review 3.  Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach.

Authors:  Francesca Sperotto; Kevin G Friedman; Mary Beth F Son; Christina J VanderPluym; Jane W Newburger; Audrey Dionne
Journal:  Eur J Pediatr       Date:  2020-08-15       Impact factor: 3.183

4.  Value of serial echocardiography in diagnosing Kawasaki's disease.

Authors:  Maria Hörl; Holger Michel; Stephan Döring; Markus-Johann Dechant; Florian Zeman; Michael Melter; Stephan Gerling
Journal:  Eur J Pediatr       Date:  2020-09-21       Impact factor: 3.183

5.  Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study.

Authors:  Xuting Zhang; Yuee He; Yiping Shao; Biyao Hang; Zhipeng Xu; Maoping Chu
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-26       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.